북미의 말라리아 치료제 시장 : 지역별 분석 : 치료제별, 투여 경로별, 유통 채널별 예측(-2030년)

The North America malaria treatment market was valued at US$ 62.97 million in 2022 and is expected to reach US$ 487.31 million by 2030; it is estimated to grow at a CAGR of 29.1% from 2022 to 2030.

Increasing Prevalence of Malaria Fuels North America Malaria Treatment Market

Malaria, one of the acute febrile illnesses, is caused by plasmodium parasites and spreads through the infected female Anopheles mosquitoes. Five parasite species in humans mainly cause malaria, and two of these species-Plasmodium falciparum and P. vivax-are considered the greatest threat to human health. Also, P. falciparum is the deadliest malarial parasite, and it is most widely spread across the African continent. Further, P. vivax is the dominant malarial parasite in most countries outside of sub-Saharan Africa. According to the latest World Malaria Report (WMR) 2020 from the World Health Organization (WHO), 241 million cases of malaria were reported in the world, in comparison to 227 million cases that were logged in 2019. According to the same source, the number of deaths caused due to malaria has an annual rise of 69,000 deaths. Approximately two-thirds of these deaths, i.e., 47,000, were caused by disruptions in healthcare services during the COVID-19 outbreak; the remaining one-third of deaths, i.e., 22,000 reflected a recent change in the WHO's methodology for calculating malaria mortality (irrespective of COVID-19 disruptions). Thus, the rising prevalence of malaria boosts the malaria treatment market growth.

North America Malaria Treatment Market Overview

According to the Centers for Disease Control and Prevention (CDC), approximately 2,000 cases of malaria are reported annually in the US, mostly in travelers from other countries and immigrants. Pregnant women and children under 5 years of age are at the highest risk of contracting malaria and developing severe diseases. There is a perpetual risk that malaria transmission can resume in the US due to the endurance of anopheles mosquitoes (vectors) capable of transmitting malaria in the US. According to the Global Fund data from April 2022, cases and deaths related to malaria rose mainly due to stalled funding and disruptions caused by the COVID-19 pandemic. However, efforts to moderate these impacts have seen progress, as mentioned in the Global Fund report in September 2022. Efforts taken by the US government to control malaria include activities primarily through the US President's Malaria Initiative (PMI), overseen by the US Global Malaria Coordinator. According to Global Health Policy, US funding for malaria control and research activities was approximately US$ 1 billion in FY 2022. The US government's goal under the PMI Strategy 2021-2026 is to work and reduce deaths caused by malaria and decrease malaria morbidity, in turn approaching its long-term goal of elimination.

Thus, the malaria treatment market growth in the US is driven by the rising number of malaria patients.

North America Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Malaria Treatment Market Segmentation

The North America malaria treatment market is segmented based on treatment, route of administration, distribution channel, and country. Based on treatment, the North America malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The vaccines segment held the largest market share in 2022.

In terms of route of administration, the North America malaria treatment market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2022.

By distribution channel, the North America malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.

Based on country, the North America malaria treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America malaria treatment market share in 2022.

Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, and Lupin Ltd are some of the leading players operating in the North America malaria treatment market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights - Malaria

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. North America Malaria Treatment Market - Key Industry Dynamics

• 4.1 Key Market Drivers:
  • 4.1.1 Increasing Prevalence of Malaria
  • 4.1.2 Rising Initiatives to Raise Awareness about Malaria
• 4.2 Market Restraints
  • 4.2.1 Availability of Counterfeit Antimalarial Drugs Followed by Subsequent Drug Resistance
• 4.3 Market Opportunities
  • 4.3.1 Growing Strategic Initiatives by Market Players
• 4.4 Future Trends
  • 4.4.1 Extending Pipeline of New Drugs and Vaccines
• 4.5 Impact Analysis

5. Malaria Treatment Market - North America Market Analysis

• 5.1 North America Malaria Treatment Market Revenue (US$ million), 2022 - 2030

6. North America Malaria Treatment Market - Revenue and Forecast to 2030 - by Treatment

• 6.1 Overview
• 6.2 North America Malaria Treatment Market Revenue Share, by Treatment 2022 & 2030 (%)
• 6.3 Vaccines
  • 6.3.1 Overview
  • 6.3.2 Vaccines Market Revenue and Forecast to 2030 (US$ Mn)
• 6.4 Generic Drugs
  • 6.4.1 Overview
  • 6.4.2 Generic Drugs Market Revenue and Forecast to 2030 (US$ Mn)
• 6.5 Originators
  • 6.5.1 Overview
  • 6.5.2 Originators Market Revenue and Forecast to 2030 (US$ Mn)
• 6.6 Others
  • 6.6.1 Overview
  • 6.6.2 Others Market Revenue and Forecast to 2030 (US$ Mn)

7. North America Malaria Treatment Market - Revenue and Forecast to 2030 - by Route of Administration

• 7.1 Overview
• 7.2 North America Malaria Treatment Market Revenue Share, by Route of Administration 2022 & 2030 (%)
• 7.3 Oral
  • 7.3.1 Overview
  • 7.3.2 Oral: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Parenteral
  • 7.4.1 Overview
  • 7.4.2 Parenteral: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Malaria Treatment Market - Revenue and Forecast to 2030 - by Distribution Channel

• 8.1 Overview
• 8.2 North America Malaria Treatment Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• 8.3 Direct Tender
  • 8.3.1 Overview
  • 8.3.2 Direct Tender: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Hospital Pharmacies
  • 8.4.1 Overview
  • 8.4.2 Hospital Pharmacies: Malaria Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.4.2.1.1 Malaria Treatment Market, by Hospital Pharmacies
• 8.5 Retail Pharmacies
  • 8.5.1 Overview
  • 8.5.2 Retail Pharmacies: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.5.2.1.1 Malaria Treatment Market, by Retail Pharmacies
• 8.6 Online Pharmacies
  • 8.6.1 Overview
  • 8.6.2 Online Pharmacies: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 8.7 Others
  • 8.7.1 Overview
  • 8.7.2 Others: Malaria Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Malaria Treatment Market - Country Analysis

• 9.1 North America Malaria Treatment Market, Revenue and Forecast To 2030
  • 9.1.1 Overview
    • 9.1.1.1 North America: Malaria Treatment Market, by Country
    • 9.1.1.2 US
    • 9.1.1.3 Overview
      • 9.1.1.3.1 US: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.3.2 US: Malaria Treatment Market, by Treatment
      • 9.1.1.3.3 US: Malaria -Malaria Treatment Market, by Route of Administration
      • 9.1.1.3.4 US: Malaria Treatment Market, by Distribution Channel
      • 9.1.1.3.4.1 US: Malaria Treatment Market, by Hospital Pharmacies
      • 9.1.1.3.4.2 US: Malaria Treatment Market, by Retail Pharmacies
    • 9.1.1.4 Canada
    • 9.1.1.5 Overview
      • 9.1.1.5.1 Canada: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.5.2 Canada: Malaria Treatment Market, by Treatment
      • 9.1.1.5.3 Canada: Malaria -Malaria Treatment Market, by Route of Administration
      • 9.1.1.5.4 Canada: Malaria Treatment Market, by Distribution Channel
      • 9.1.1.5.4.1 Canada: Malaria Treatment Market, by Hospital Pharmacies
      • 9.1.1.5.4.2 Canada: Malaria Treatment Market, by Retail Pharmacies
    • 9.1.1.6 Mexico
    • 9.1.1.7 Overview
      • 9.1.1.7.1 Mexico: Malaria Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.7.2 Mexico: Malaria Treatment Market, by Treatment
      • 9.1.1.7.3 Mexico: Malaria -Malaria Treatment Market, by Route of Administration
      • 9.1.1.7.4 Mexico: Malaria Treatment Market, by Distribution Channel
      • 9.1.1.7.4.1 Mexico: Malaria Treatment Market, by Hospital Pharmacies
      • 9.1.1.7.4.2 Mexico: Malaria Treatment Market, by Retail Pharmacies

10. Malaria Treatment Market Industry Landscape

• 10.1 Overview
• 10.2 Growth Strategies in the Malaria Treatment Market
• 10.3 Inorganic Growth Strategies
  • 10.3.1 Overview
• 10.4 Organic Growth Strategies
  • 10.4.1 Overview

11. Company Profiles

• 11.1 Cipla Ltd
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Sun Pharmaceutical Industries Ltd
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 Sanofi SA
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 GSK Plc
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Novartis AG
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Pfizer Inc
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Service
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 AdvaCare Pharma USA LLC
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments
• 11.8 VLP Therapeutics LLC
  • 11.8.1 Key Facts
  • 11.8.2 Business Description
  • 11.8.3 Products and Services
  • 11.8.4 Financial Overview
  • 11.8.5 SWOT Analysis
  • 11.8.6 Key Developments
• 11.9 Lupin Ltd
  • 11.9.1 Key Facts
  • 11.9.2 Business Description
  • 11.9.3 Products and Services
  • 11.9.4 Financial Overview
  • 11.9.5 SWOT Analysis
  • 11.9.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms